Introduction: High-titre factor VIII (FVIII) inhibitors complicate peri-operative haemostasis. Recombinant porcine FVIII (r-pFVIII) may provide an alternative haemostatic agent for high-risk procedures and allow FVIII activity monitoring. Aim: Devise an effective haemostatic plan for repair of a progressively symptomatic aortic coarctation in a 5-year-old male with immune tolerance induction (ITI) refractory high-titre FVIII inhibitors. Methods: Preprocedure human FVIII inhibitor titre was 58 Bethesda Units mL À1 (BU) and cross-reacted to neutralize porcine FVIII at 30 BU. Daily ITI with plasma-derived FVIII concentrate was supplemented with anti-B-cell and anti-plasma cell immunotherapy to reduce FVIII inhibitor titres. Potential haemostatic agents were evaluated in comparative ex vivo thrombin generation assays (TGA). Results: Four weeks after immunosuppression, human and porcine inhibitor titres declined to 16 and 2 BU respectively. TGA with r-pFVIII was less robust than with activated prothrombin complex concentrate (aPCC); however, r-pFVIII was selected for cardiac surgery to secure the ability to assay FVIII levels throughout this high-bleeding risk procedure. Haemostasis with r-pFVIII was excellent; initial trough FVIII activity levels ranged from 0.81-1.17 IU mL
Introduction
The presence of high-titre neutralizing alloantibodies (inhibitors) complicates the peri-operative haemostasis management for patients with haemophilia. Bypassing agents (BPA), activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa) currently provide the mainstay of treatment [1] [2] [3] ; however, inconsistent haemostatic effect and lack of validated laboratory assays for pharmacodynamic monitoring limit the advantages of these agents [4, 5] . Recombinant porcine FVIII (r-pFVIII, OBIZUR, Shire) received orphan drug designation for acquired haemophilia A (AHA) in adults and was licensed in 2014 [6, 7] . The majority of human FVIII (hFVIII) inhibitors targets the A2 and C2 domains, creating allosteric hindrance to activation. The reduced sequence homology between hFVIII and porcine FVIII (pFVIII) at these domains, 84% and 76% respectively, enables effective pFVIII replacement in humans [8] .
Limited studies, focused primarily on comparative pharmacokinetic profiles with plasma-derived pFVIII (pd-pFVIII, Hyate-C, Ipsen), were conducted in patients with congenital haemophilia A and inhibitors until its production was discontinued in 2004. RpFVIII demonstrated greater recovery and AUC compared to pd-pFVIII and a mean half-life of 11 h [9] . Even in the absence of prior exposure to pFVIII, hFVIII inhibitors can cross-neutralize pFVIII activity, impacting the potential efficacy of r-pFVIII [6, 9] . Use of global measures of haemostasis, such as thrombin generation assays, may guide selection of the optimal peri-procedure haemostatic agent for a given patient to minimize risk of bleeding [10, 11] .
While use of pd-pFVIII has been well described for congenital haemophilia with inhibitors, minimal investigation of r-pFVIII has been conducted in this population [12] . Here, we present our experience using r-pFVIII for a paediatric patient with high-titre inhibitors requiring cardiac surgery for repair of progressively symptomatic hypoplastic aortic arch and coarctation.
Materials and methods

Patient
The patient was a 5-year-old male diagnosed with severe haemophilia A (nonsense mutation in the F8 gene (FVIII c.6853C>T)) and emergence of very high-titre inhibitors at age 14 months. Peak inhibitor titre was 563 BU prior to any attempt at immune tolerance induction (ITI). An incidental diagnosis of hypoplastic transverse arch and aortic coarctation was made during an echocardiogram for central venous line (CVL) evaluation at 18 months of age. Plans for an open heart surgical approach included the anticipated need for cardiopulmonary bypass and intraoperative anticoagulation. Definitive repair was initially deferred due to lack of systemic hypertension, the acceptable ascending-to-descending aortic gradient, and the significant bleed risk with cardiac repair secondary to his high-titre FVIII inhibitors.
During the interval between the development of high-titre inhibitors and the patient's symptom progression necessitating aortic repair, several attempts at ITI were made. Initially, a high-dose daily FVIII concentrate regimen was used, then immunosuppression regimens, including mycophenolate as monotherapy and later combined B-and T-cell immune modulation with rituximab, mycophenolate, intravenous immunoglobulin and dexamethasone as per Beutel et al. were added [13] . The peak inhibitor titre following start of ITI #1 was 3967 BU. Despite multiple approaches to ITI spanning more than 2 years, hightitre inhibitors persisted (30-100 BU; Fig. 1a) . Use of rFVIIa for daily prophylaxis and peri-operatively for CVL placement yielded suboptimal clinical outcomes with breakthrough musculoskeletal haemorrhages and poor postoperative haemostasis. The patient subsequently underwent operative central venous port-acath replacement under coverage of aPCC without bleeding complications.
Thrombin generation measurements
Given the anticipated need for definitive aortic repair despite persistent high-titre inhibitor, preoperative characterization of the patient's thrombin generation in response to bypassing agents was evaluated. Blood collection and analyses were performed after obtaining approval from the University of North Carolina Institutional Review Board and informed consent. TGA were performed using both platelet-rich (data not shown) and platelet-poor plasma to characterize the relative thrombin generation of r-pFVIII, rFVIIa and aPCC at a time when the patient's hFVIII and pFVIII inhibitor titres were 37 and 3 BU respectively. This patient had no prior exposure to porcine FVIII.
Blood collected from the patient at baseline (prior to infusion of his daily ITI dose of FVIII/VWF concentrate) was spiked in vitro with r-pFVIII, rFVIIa, or ). Reactions with platelet-rich and platelet-poor plasma were performed with 1 pM tissue factor and 1 pM tissue factor per 4 lM phospholipids respectively [14] .
Preoperative ITI and immunosuppressive regimen
Subsequent to the thrombin generation measurements, an interval increase in both human and porcine inhibitor titres was observed, hFVIII inhibitor titre 58 BU and pFVIII inhibitor 30 BU, despite absence of exposure to pFVIII. Prophylaxis and bleed treatment with aPCC and ITI were ongoing. Safety and efficacy of r-pFVIII has not been established in patients with a porcine factor VIII inhibitor titre of greater than 20 BU [7] . A preoperative attempt to minimize both human and porcine inhibitor titres was begun with ITI consisting of continuing antihemophilic factor/von Willebrand factor complex with the addition of a single dose of rituximab 375 mg m À2 on day 1 and bortezomib 1.3 mg m À2 on days 1, 4, 8 and 11 (following the regimen of Khandelwal et al., however omitting plasmapheresis) [15] . Following administration of initial immunosuppressive agents, human and porcine anti-FVIII titres were measured every 2 weeks.
Peri-operative haemostasis measurements
Human and porcine Bethesda Inhibitor Assays and clinical thromboelastography (TEG) were performed at the McLendon Clinical Laboratories at the University of North Carolina (TEG-analyzer, Haemonetcis Corp., Braintree, MA, USA), trigger kaolin. Intraoperative and postoperative one-stage FVIII activity assays were performed in the clinical coagulation laboratory at Boston Children's Hospital.
Results
By the age of 5 years, an increasing coarctation gradient indicated that aortic repair was necessary. The high bleed risk of the cardiac repair to be performed and possible need for thoracotomy and cardiac bypass made desirable the ability to monitor therapeutic FVIII levels and respond with tailored dosing as needed. Inhibitor titres were confirmed to have decreased to 16 BU hFVIII and 2 BU pFVIII at 4 weeks following bortezomib and rituximab and 2 weeks prior to the patient's aortic repair (Fig. 1b) .
Prospective haemostatic evaluation to support cardiac repair and recovery
Evaluation of thrombin generation in the patient's platelet-poor plasma in response to r-pFVIII or bypassing agent ex vivo supplementation, collected at a baseline state of health, is shown in (Fig. 2a) . (Fig. 2b) . The observed potential to normalize clot parameters using aPCC was also confirmed by whole blood TEG performed ex vivo following aPCC infusion (Fig. 2c) . The in vitro and ex vivo TGA evaluation, the clinical TEG results and the haemostatically benign clinical course during CVL placement and healing all suggested that aPCC may provide haemostatic support during the anticipated weeks of normal wound healing following aortic repair. Nevertheless, the opportunity to monitor and manage FVIII activity levels led to the choice of r-pFVIII for haemostasis during the aortic repair.
Operative and postoperative haemostatic management
The preincision r-pFVIII dose, FVIII activity assay monitoring plan and subsequent r-pFVIII dosing schedule for this paediatric patient were developed by considering the reported experience with r-pFVIII in acquired haemophilia A [6, 7] , prior description of r-pFVIII pharmacokinetic profile in adolescent and adult patients with congenital haemophilia [9, 16, 17] and the patient's baseline porcine inhibitor titre. The absence of available product stability testing prevented use of continuous r-pFVIII infusion for this case. A preprocedure r-pFVIII test dose was not administered to characterize recovery or estimate half-life for this patient due to concern for prematurely stimulating an anamnestic increase in the porcine inhibitor titre [16, 18] .
At incision, r-pFVIII 170 IU kg À1 was administered; FVIII activity was 0.85 IU mL À1 at 60 min postinfusion. A left posterolateral muscle-sparing thoracotomy and repair of the aortic arch with resection of hypoplastic segment and end-to-end aortic anastomosis were performed. Sternotomy and cardiopulmonary bypass were ultimately not required. The patient achieved excellent haemostasis throughout the 3-h procedure. Subsequent r-pFVIII dosing at 100 IU kg À1 dose À1 was started at an interval of every 3 hours, then the time between infusions was increased based on trough levels and clinical examination for bleeding (Fig. 3 ). The target trough FVIII level for the first 24 hours postprocedure was greater than 0.8 IU mL À1 and thereafter greater than 0.5 IU mL
À1
.
Limited vial size availability (only nominal concentration 500 U mL À1 ) and lag time in reporting trough levels constrained weaning the dose of r-pFVIII. Following the initial r-pFVIII dose, the patient received three doses at 3-h intervals, two doses at 4-h intervals, one dose at a 6-h interval, then five doses at 8-h intervals.
Initially, trough FVIII activities ranged from 0.81 to 1.17 IU mL
; however, at the time of his 10th dose (day 3, fourth dose on an every 8-h schedule), the trough level plummeted to 0.13 IU mL À1 with subsequent recovery of 1.13 IU mL À1 (49% of expected) following dose 11. Arterial line, chest tube and internal jugular venous catheter were removed. The subsequent trough and peak FVIII activities around dose 12 were 0.1 and 0.69 IU mL À1 (34% of expected) respectively. Given evidence of increasing r-pFVIII neutralization, haemostatic treatment was transitioned to aPCC 85 IU kg À1 dose À1 every 12 hours on postprocedure day 3. The patient continued to have excellent haemostasis and was discharged home by day 5 postprocedure.
Plasma for FVIII inhibitor titres was drawn at first concern for rising inhibitor and assayed at 12.5 BU, human and 0.5 BU, porcine. Subsequent titres measured 12 days postprocedure were at 64 BU, human and 13 BU, porcine. These titres waned over the subsequent 4 weeks to 50 and 5 BU respectively. The patient continues ITI with antihemophilic factor/von Willebrand factor complex (153 IU kg À1 day
) and aPCC prophylaxis (88 IU kg À1 every other day).
Discussion
The emergence of pd-pFVIII in the 1960s provided a therapeutic option for congenital haemophilia A patients with life-threatening bleeds at a time when concentrated human FVIII products were scarce. Despite improved fractionation procedures, which reduced common adverse events of hypersensitivity reactions and thrombocytopenia [8, 12, 18] , the commercially available product, Hyate-C, discontinued production in 2004 due to concern for viral contamination (porcine parvovirus and retroviruses) [19] .
The recent licensure of a recombinant porcine FVIII product for AHA has again expanded therapeutic options for patients with FVIII inhibitors; however, this product has not yet been well studied in the congenital haemophilia patients. This case demonstrates the successful off-label use (by indication, age and dosing) of r-pFVIII. Alloantibodies to FVIII pose the greatest challenge to the treatment of haemorrhage and peri-operative haemostasis management in patients with haemophilia. The inability to anticipate and monitor the haemostatic effect of BPA makes their use in the management of high-risk bleeding challenging. RpFVIII offers an alternate option where measurement of therapeutic effect through a one-stage clotting assay supports optimal clinical outcomes, namely effective haemostasis and protection from recurrent haemorrhage.
Comparative use of r-pFVIII in acquired haemophilia and congenital haemophilia with inhibitors
The dosing strategy used in the pivotal study for AHA included an initial dose of 200 IU kg À1 followed by subsequent doses of a median of 100 IU kg À1 approximately every 8 hours to maintain FVIII activity levels >50% (or as desired). Approximately, one third of patients with AHA demonstrated positive pFVIII titres prior to exposure to r-pFVIII, with a mean cross-reactivity in this patient subset of 24.5% (porcine FVIII inhibitor titre/human FVIII inhibitor titre) [6] .
Therapeutic FVIII activity levels were achieved upon repeated doses of r-pFVIII even in the patients with cross-reactivity. This trend was also observed in our patient. While the presence of cross-reacting FVIII inhibitors is generally not established at initial haemorrhagic presentation of AHA, pre-emptive testing for porcine inhibitor titres may be completed for congenital haemophilia patients with inhibitors prior to r-pFVIII use. The current label-recommended dosing guidance is tailored towards the acquired haemophilia population. Care must be taken in the congenital haemophilia population to investigate an optimal approach to dosing and infusion schedule. Historical experience with pd-pFVIII provides some guidance; however, the pharmacokinetic profiles of pd-pFVIII and r-pFVIII are not identical.
Comparative costs of therapeutic options
Accessibility and cost of care are necessary considerations. The inpatient cost per unit of r-pFVIII at Boston Children's Hospital is approximately $4.67 per IU. Measurable haemostasis for 62 h (12 doses) with rpFVIII led to an estimated cost of $103,300 prior to transition to aPCC for ongoing bleed prevention and wound healing. Using our typical BPA dosing strategies' cost of haemostasis for the first 62 hours would be approximately $63,141 for rFVIIa and $16,269 for aPCC (Table 1) . Given the high-risk nature of this procedure the 'value-added' of being able to monitor haemostasis in near-real time without having to respond only to insufficient haemostasis (frank bleeding symptoms) made the r-pFVIII worthwhile during the intraoperative and early postoperative period. Judicious use of r-pFVIII, such as for critical high-risk surgical procedures or emergent bleeding, may be appropriate. Frequent re-assessment of when bypassing agents can be introduced for ongoing Time post-incision (h) Factor VIII Activity (IU mL -1
)
Trough pFVIII activity levels Peak pFVIII activity levels r-pFVIII doses Fig. 3 . Peri-operative r-pFVIII replacement schedule and resulting peak and trough FVIII activity levels. Peri-operative dosing of r-pFVIII (closed triangles, ▼) was initiated at a dose of 170 IU kg À1 at the time of incision for aortic repair, hour 0. Subsequent doses of 100 IU kg À1 were administered at increasing intervals as indicated. Peak FVIII activity levels (open diamonds, ♢) and trough FVIII activity levels (closed squares, ■) sampled around early postoperative doses and at later points when r-pFVIII activity was less sustained.
haemostasis is needed to ensure optimal balance of patient care and cost.
